Dr L Standker, DSc, studied biochemistry in Hannover (Germany) and obtained a PhD under the supervision of W.G. Forssmann on novel peptide therapeutics. Currently, he is scientific director at Pharis Biotec GmbH and established a centre of excellence in Ulm as part of Ulm Peptide Pharmaceuticals. LS published extensively on fused therapeutic peptides for the treatment of HIV-AIDS. He holds and commercialised a comprehensive patent portfolio on chemotherapeutic peptide mimetics for antivirals and anticancer agents.